In its original, generalized form, the immune surveillance theory has postulated that (i) tumor cells arise in the normal organism at an "enormous frequency" and (ii) they are regularly eliminated by immune mechanisms (1). Most of the recent experimental work in tumor immunology is based on this assumption, with or without modifications, consciously or by implication. As a result, attempts are focused on the demonstration and characterization of the "immunological failure" that is assumed to bear the primary responsibility for tumor development in the cancer patient.
ABSTRACT Spontaneous tumors are defined as tumors that develop in the absence of all experimental interference. In contrast to the widely documented, strong rejection reactions against most virus-induced tumors, spontaneous tumors evoke little or no detectable rejection reaction in intact or preimmunized syngeneic hosts. The difference can be viewed in relation to the contrasting natural history of the two conditions. Spontaneous tumors evolve in several steps, as a rule. "Tumor progression" is a microevolutionary process at the level of the somatic tissue where successive clonal variants replace each other. Each new variant gains the upper hand due to its greater independence of some restricting host mechanism. Independence of immune restrictions must be part of this process. Host selection for immune resistance apparently plays no major role here, presumably because most of the naturally occurring tumors arise after the host has passed the peak of its reproductive period.
Protection against the oncogenic effects of ubiquitous tumor viruses is, on the other hand, the result of host selection for immune mechanisms favoring prompt rejection of virus-transformed cells. This is neither synonymous with nor related to protection against the viral infection per se, which is frequently successful and usually quite harmless. A certain relationship can be perceived between the degree of viral ubiquity and the strength of immune protection against the corresponding tumor cells. Natural selection for host recognition of commonly occurring, virally induced changes in neoplastic cell membranes can be surmised to occur, at least in part, by the fixation of appropriate immune responsiveness (Ir) genes. The role of Ir genes for tumor recognition can be approached by the genetic analysis of the F1 hybrid resistance effect. Unresponsiveness to spontaneous tumors may be overcome by target-cell modification, e.g., by chemical coupling, somatic cell hybridization, or viral "xenogenization."
In its original, generalized form, the immune surveillance theory has postulated that (i) tumor cells arise in the normal organism at an "enormous frequency" and (ii) they are regularly eliminated by immune mechanisms (1) . Most of the recent experimental work in tumor immunology is based on this assumption, with or without modifications, consciously or by implication. As a result, attempts are focused on the demonstration and characterization of the "immunological failure" that is assumed to bear the primary responsibility for tumor development in the cancer patient.
Recently, the surveillance concept has been criticized by several authors. The relative rarity of primary tumors in thymusless (nude) mice is often used as the main argument. Even if this observation is true and not merely an artefact due to the short survival and poor health of these animals in most laboratories, the argument completely overlooks the well-documented fact that nude mice possess powerful non-T-cell-mediated surveillance mechanisms (2-4). A more serious case can be made on the basis of the well-demonstrated but frequently overlooked inability of spontaneous tumors to immunize autochthonous or syngeneic hosts.
In this article, the word spontaneous refers to tumors that have arisen without any experimental interference in the laboratory or in nature. In this context, inbreeding with selection for high tumor incidence must be regarded as very serious experimental interference; we shall therefore avoid considering tumors of this category as far as possible. Baldwin (5) (10) . Antiviral immunity was neither necessary nor sufficient to bring about rejection, while immunization with virus-nonproducer, polyoma-induced tumors (syngeneic or allogeneic) effectively protected mice against the isografting of already established polyoma tumors. In Marek's disease, vaccination against the related but apathogenic turkey herpesvirus (HVT) could protect against tumor development, but not against virus shedding (11, 12) . The mammalian Rous sarcoma virus system is entirely nonpermissive and antiviral immunity cannot play any role in the relatively strong protection observed (13) , to mention only a few examples. (15) . There is also suggestive evidence that T-cellmediated responses may restrain the proliferation of EBVtransformed bone-marrow-dependent (B) blasts in acute infectious mononucleosis (16) and may "lose out" in competition with progressively growing, EBV-carrying B-lymphoma cells in the Burkitt tumor (17) . There is no corresponding information for the herpesvirus saimiri system, although it is interesting to note that the naturally resistant squirrel monkey host responds to virally induced antigens more promptly than the tumor-susceptible marmoset and owl monkey (18) .
Feline leukemia virus reflects a somewhat different situation. It is much less ubiquitous than the viruses discussed above; the exact frequency of virus-carrying street cats is not known, but it is estimated to range between 0.1 and 1% (19) . The risk of leukemic development in the virus-infected cat is around 5%. There is suggestive evidence that non-T-cell mechanisms may play a protective role against this T-cell disease (19, 20) . Antibody to a virally determined but nonviral membrane antigen (FOCMA) appears to play an important part, alone or in concert with cellular effectors.
The "intermediate" resistance of cats to the leukemogenic effect of feline leukemia virus, inferior to the complete resistance in the above systems but nevertheless protective for the majority of the infected animals, may be attributed to an "intermediate" selective impact of the virus, with less ubiquity and perhaps even a less ancient history.
At the far end of the susceptibility scale we find Marek's disease virus (MDV). This virus is not a normal contaminant of healthy chicken breeds. Some countries (e.g., Sweden) have been free of the disease altogether. Upon infection, Marek's disease virus causes a virulent epizootic disease with full expression of the oncogenic effect and high mortality. The protective effect of turkey herpesvirus vaccination (not merely an antiviral effect, as already mentioned) shows that the birds are responsive to virally induced, tumor-associated antigens. Relatively resistant fowl strains exist, and, in certain crosses, resistance was found to be under the control of a single dominant gene (11, 12, (21) (22) (23) . Recently (22, 23) , a linkage was found between a resistance gene and the major histocompatibility complex. It appears likely that Ir genes contribute to genetic resistance.
In conclusion, the admittedly fragmentary story on the relationship between known oncogenic viruses and their natural host species suggests the following:
(i) Resistance against the development of virus-induced tumors is mainly if not entirely due to immune responses against virally determined cell antigens, not against viral multiplication per se.
(ii) Resistance is often mediated through T-cell-dependent mechanisms. This may include T-killer cells and/or indirect, T-cell dependent (e.g., antibody-mediated) effects. The relative role of T-cell-independent mechanisms is not clear but there are strong indications that they may play a certain role, at least in some systems (2, 3, 15, 19, 20) .
(iii) Ubiquitous viruses appear to have preselected their host species for immunologically mediated resistance against their preneoplastic or frankly neoplastic ("transformed") cell products. Enzootic viruses may have been less efficient and resistance may be only partial. Tumor epizootics may be induced by viruses that infect susceptible and previously largely unexposed hosts.
(iv) It is a particularly important corollary of these considerations that virus-induced, tumor-associated membrane changes can be regularly recognized as antigenic, independently of virus production (i.e., even in completely nonpermissive systems). It (27) , the H-2 linked Rgv-ls allele (28) that is probably analogous to the unresponsive form of an Ir gene, and genetic susceptibility at the target cell level, favoring neoplastic transformation (29) . In spite of this cumulation of susceptibility factors, leukemia develops only after a latency of several months. When it appears, the cells usually carry one (or more rarely several) extra chromosomes (30) . It is known that the thymus of AKR mice is highly abnormal long before leukemia development and contains a substantial number of "preleukemic" cells. Conceivably, the virus induces a preleukemic condition only and further cytogenetic evolution is required to achieve full malignancy. The EBV-associated Burkitt lymphoma is another case in point. Between 80 and 90% of all tumors and derived, established lines were found to carry a highly specific 14q+ chromosome marker, with an extra band at the distal end of the long arm of one chromosome 14 (31) (32) (33) . The remaining 10-20% tumors had other chromosomal anomalies; none of them were purely diploid. In contrast, EBV-transformed cell lines derived from normal EBV-positive donors, or infectious mononucleosis patients, or other nonmalignant sources were often diploid. In no case were they found to contain the 14q+ marker. Even if normal peripheral lymphocytes of Burkitt lymphoma patients with 14q+ positive tumors were transformed by EBV in vitro, the derived, established lines lacked the marker and were purely diploid (33) .
The cellular genome exerts an important influence on the apparently more direct in vitro transformation induced by the small DNA viruses, polyoma or simian virus 40, in sensitive monolayer cultures (25) . This can be exemplified by (i) the occurrence of virus-carrying phenotypic revertants, with maintained, integrated viral DNA and T-antigen but a changed chromosomal constitution (34); (ii) the demonstration that a temperature-sensitive mutation in a cellular function can control the transformed phenotype without any change in the viral genome (35) ; and (iii) the suppression of the virally induced malignant phenotype by hybridization with normal cells, in spite of continued viral antigen expression (36) .
The likelihood that tumor-associated chromosomal changes play an important role in the neoplastic process is also suggested by their nonrandom nature (37, 38) . Specific and reproducible chromosomal changes are associated with certain forms of tumor development, different for different etiological agents.
Tumor progression was defined by Foulds (24) as the gradual evolution of a tumor towards increased autonomy by a series of stepwise changes in multiple unit characteristics. He particularly stressed the independent progression of various unit characteristics, i.e., their ability to reassort in many different combinations, and concluded that each form of autonomous neoplasia may evolve along a variety of alternative pathways. Table 2 lists some of the relevant unit characteristics of tumor progression. It is interesting to contrast the in vivo properties of Foulds against the "more modern" in vitro parameters, based on cell behavior in artificial culture systems. It has been a general experience that the in vitro "correlates" of neoplastic behavior do not faithfully reflect tumorigenicity in vivo, although they may represent parts of the whole. Each part ap-pears to be interchangeable and none of them is absolutely necessary. This is in line with the rules of Foulds for in vivo progression.
Somatic cell hybridization between in vitro transformed and/or tumorigenic cells and normal cells showed, paradoxically, dominance of the in vitro transformed phenotype but suppression of tumorigenicity, as long as the hybrids carried most of the chromosomes of both parental cells (39) . This apparent contradiction may be resolved if the various transformation characteristics in vitro represent parts of the whole, i.e., tumorigenicity. If so, negative ("repressive") control of only one partial characteristic is already sufficient to provide the impression that in vivo tumorigenicity as a whole is also under negative control.
The logical connection between tumor progression and the nonrejectability of spontaneous tumors As discussed above, current experimentation in tumor immunology is often based on the notion that most, if not all, tumors are potentially rejectable in the autologous host and tumor growth is therefore a failure of the rejection response. Experimental evidence on spontaneous tumors does not support this concept, however. One might regard this as the "central fallacy" of tumor immunology.
The poor rejectability of spontaneous tumors may have two main reasons:
(i) During tumor progression, immune restrictions are only one among the many categories of homeostatic growth-controlling forces. Tumor progression represents the gradual and essentially clonal evolution of independence from these restrictions, step by step, property by property. This process is likely to involve the selection of cells with decreased immunogenicity and/or resistance to immune effectors.
(ii) It 
